experimenta;l | THE "NEW" PROSTATE CANCER INFOLINK

Follow The "New" Prostate Cancer InfoLink news blog on TWITTER or FACEBOOK.
The "New" Prostate Cancer InfoLink has been developed to become a primary source of accurate, current, and topical information about prostate cancer for patients and their families.
A service of

Prostate Cancer International.
Awards
Other PCI web sites

El Cáncer de Próstata Latinoamérica
Prostate Cancer Africa
Prostate Cancer Caribbean
Solidarité Prostate InfoLink
Copyright © 2008-18 Prostate Cancer International, Inc.

Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

Posted on December 23, 2016 by Sitemaster

The nuclear medicine group at the University of Heidelberg in Germany recently reported a complete response in two patients treated with Ac-225-PSMA-617 (see this link). … READ MORE …

Filed under: Drugs in development, Management, Treatment | Tagged: actinium-225, experimenta;l, outcome, PSMA-617 | 6 Comments »

The language of denial of access to high-quality prostate cancer care today

Posted on October 24, 2016 by Sitemaster

If you look at the corporate web site for eviCore Healthcare, the company describes itself as follows: … READ MORE …

Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: classification, experimenta;l, guideline, investigational | 6 Comments »

THE "NEW" PROSTATE CANCER INFOLINK

A service of

Awards

Other PCI web sites

Ac-225-PSMA-617 apparently extends survival of very late-stage patients: an update

The language of denial of access to high-quality prostate cancer care today

Disclaimer

Hot Posts …

… and Archives